Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ltz-301
Follicular Lymphoma
LTZ Therapeutics, Inc.
P1
CC
(43)
Ltz-301
Marginal Zone Lymphoma
LTZ Therapeutics, Inc.
P1
CC
(43)
lu-177 labeled 6a10-fab-fragments
Glioblastoma
University Hospital Muenster
P1
CC
(43)
[Lu-177]-Pnt6555
Cholangiocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Colorectal Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Esophageal Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Head And Neck Squamous Cell Carcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Cutaneous Melanoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Pancreatic Ductal Adenocarcinoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
[Lu-177]-Pnt6555
Soft Tissue Sarcoma
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
P1
CC
(43)
lu 177-psma-3d1015
Castration-Resistant Prostate Carcinoma
Chunjing Yu
P1
CC
(43)
Lu Ag06466
Focal Epilepsy
H. Lundbeck A/S
P1
CC
(43)
Lucar-20Sp Cells
B-Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
P1
CC
(43)
Lucar-G39P Cells Product
B-Cell Non-Hodgkin Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P1
CC
(43)
Lung Spheroid Stem Cells 200 Million
Idiopathic Pulmonary Fibrosis
University of North Carolina, Chapel Hill
P1
CC
(43)
Lunresertib
Uterine Cancer
University Health Network, Toronto
P1
CC
(43)
Lutetium [177Lu] Bl-Arc001
Digestive System Neoplasm
Sichuan Baili Pharmaceutical Co., Ltd.
P1
CC
(43)
LXP1788
Renal Cell Carcinoma
LaunXP Biomedical Co., Ltd.
P1
CC
(43)
LXP1788
Neoplasm
LaunXP Biomedical Co., Ltd.
P1
CC
(43)
LXP1788
Refractory Malignant Neoplasm
LaunXP Biomedical Co., Ltd.
P1
CC
(43)
ly007
B-Cell Non-Hodgkin Lymphoma
Ruijin Hospital
P1
CC
(43)
ly03017
Schizophrenia
Luye Pharma Group Ltd.
P1
CC
(43)
LY3143921
Colorectal Cancer
Cancer Research UK
P1
CC
(43)
LY3143921
Ovarian Serous Cystadenocarcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Non-Small Cell Squamous Lung Carcinoma
Cancer Research UK
P1
CC
(43)
Showing 3176 to 3200 of 9,920 assets
Previous
Page 128 of 397
Next
